Clinical Trial

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

Study acronym: RedeS
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety and efficacy of red blood cells (RBCs) prepared with the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in patients who require RBC transfusion support.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2017-01-27; most recent amendment 2026-03-18.
Status change: Recruiting → Active, Not Recruiting 2025-11-06
Status change: Not Yet Recruiting → Recruiting 2017-05-16
Trial Details
NCT Number NCT03037164
Lead Sponsor Cerus Corporation
Conditions Anemia
Enrollment 692 participants
Start Date 2017-05-11
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-20